SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing massive momentum as investors bet on the company's critical role in the AI-driven memory chip supercycle, with community chatter centered on explosive demand for High Bandwidth Memory and a dramatic market rerating. While bullish participants highlight the stock's long-term growth potential and structural supply tightness, others are debating whether the current parabolic price action suggests an overextended market or the early stages of a historic cycle.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors monitor potential FDA action on a key sBLA submission, while community sentiment is buoyed by reports of leadership changes at the agency and the company's aggressive international expansion strategy. Supporters remain focused on these regulatory developments and institutional buying, viewing the stock as a coiled opportunity as the market watches for imminent catalyst news.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is attracting significant investor attention following a confirmed billion-dollar colocation contract with Cerebras Systems, which the community views as a major valuation catalyst leading into the upcoming Cerebras IPO. While traders are actively debating the potential impact of share offerings on near-term price action, many remain bullish, framing the stock as an undervalued AI infrastructure play compared to its sector peers.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing heightened investor scrutiny as traders debate whether its recent earnings beat and strong market share growth justify a recovery from 52-week lows or if broader sector competition and margin concerns will continue to fuel volatility. The community remains deeply divided, with many citing the stock's significant price disconnect as an opportunity to accumulate, while others express frustration over institutional selling and concerns regarding long-term brand durability.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high-intensity trading and community debate as investors navigate recent FCC regulatory approvals alongside skepticism regarding satellite deployment timelines. Bulls are betting on a massive short squeeze and long-term potential in direct-to-device connectivity, while bears remain focused on execution risks and past missed targets ahead of the upcoming earnings report.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is trending after posting a quarterly revenue beat and announcing a multiyear partnership with AMD to build governed enterprise AI infrastructure. Community members are actively debating the company's turnaround potential, with many traders celebrating significant gains while others caution against volatility and the possibility of future share dilution.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending as investors react to a challenging earnings report and critical comments from the CEO regarding weakened consumer spending. The stock faces heavy selling pressure as community members actively debate the company's leadership, the impact of rising costs on their core demographic, and whether the recent sell-off represents a buying opportunity.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing a massive rally following a record-breaking earnings report and new, high-value launch contracts that have solidified its standing in the space infrastructure sector. The community is actively discussing the stock's aggressive momentum and price discovery, with many debating the impact of upcoming sector-wide catalysts and the potential for long-term repricing as the company secures key defense and commercial backlog growth.

Kopin Corp. engages in the development, manufacture and sale of wearable technologies which include components and systems. Its portfolio includes AMLCD, LCOS displays, OLED displays, ASIC, backlights, and optical lenses. The firm uses semiconductor material technology to design, manufacture and market its component products for use in military, enterprise and consumer electronic applications, training and simulation equipment and 3D metrology equipment. The company was founded by John C.C. Fan on April 23, 1984 and is headquartered in Westborough, MA.

Kopin Corp.

Kopin Corp

Kopin Corp is trending due to the announcement of a breakthrough MicroLED-based optical interconnect technology for AI infrastructure and a significant development order, fueling community speculation about a pivot toward high-growth AI plumbing. Investors are actively discussing the stock's potential for asymmetric upside, comparing it to other photonics players, and highlighting its role in addressing AI data center bottlenecks as a catalyst for long-term growth.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech Inc (MTEX) is trending as a low-float, highly volatile play with the community debating whether the stock is primed for a massive short squeeze or represents a classic pump-and-dump scheme. Investors are closely tracking its limited float and thin order book, with bulls looking for volume spikes to drive a parabolic move while skeptics warn of potential manipulation and lack of fundamental news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $258.00 Price Target at Royal Bank Of Canada

Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an "outperform" rating in a research note on Wednesday...

JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations

Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $265.00 Price Target at Wells Fargo & Company

Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an "overweight" rating in a research note on Wednesday...

Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Earnings Results, Beats Expectations By $1.67 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.67 by $1.67. Jazz Pharmaceuticals had a positive return on equity...

Jazz Pharmaceuticals Q1 Earnings Call Highlights

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported what executives repeatedly characterized as an exceptionally strong start to 2026, driven by double-digit growth across promoted brands and continued...

Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of +35.91% and +9.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results

Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results PR Newswire DUBLIN, May 5, 2026 Strong commercial execution...

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

JAZZ
Jazz Pharmaceuticals plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAZZ News

JAZZJazz Pharmaceuticals plc